Xylyx Bio announces exclusive license agreement with Vanderbilt University for donor organ rehabilitation asset
Xylyx Bio, a regenerative medicine company developing innovative solutions for tissue and organ repair, today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition. About Xylyx Bio: Xylyx Bio is a regenerative medicine company developing innovative approaches for tissue repair and regeneration. Xylyx Bio’s mission is to eliminate transplant waitlist mortality. Read more >>“